LHX2 CRISPR/Cas9 KO Plasmid (h): sc-401071
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LHX2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LHX2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LHX2 Antibody (LHX2A12G1): sc-81311
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LHX2 CRISPR/Cas9 KO Plasmid (h) | sc-401071 | 20 µg | $397.00 |
Overview
LHX2 (LIM homeobox 2) encodes a LIM-domain transcription factor that regulates lineage specification and tissue patterning during development, with prominent roles in neural progenitor maintenance, cortical arealization, and hair follicle morphogenesis. By binding LIM cofactors and sequence-specific DNA elements, LHX2 coordinates transcriptional programs linked to cell fate decisions, differentiation timing, and morphogen-responsive signaling networks such as WNT and SHH-dependent patterning. Dysregulated LHX2 activity has been associated with altered neurodevelopmental trajectories and with aberrant transcriptional states observed across multiple cancer contexts. As a nuclear regulator, LHX2 serves as a useful node for dissecting gene regulatory circuits that couple developmental programs to proliferative and differentiation phenotypes in human cells.
LHX2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the LHX2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the LHX2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the LHX2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LHX2 protein expression.
This CRISPR knockout system enables efficient generation of LHX2-deficient cell models for investigation of LHX2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting LHX2 exon(s) critical for LHX2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple LHX2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LHX2 CRISPR/Cas9 KO Plasmid (h) and LHX2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the LHX2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LHX2 HDR Plasmid (h) and LHX2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by LHX2 homology arms to support homology-directed repair at defined LHX2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.